Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase II trial of rPA 102 [VaxGen].

Trial Profile

Second phase II trial of rPA 102 [VaxGen].

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2014

At a glance

  • Drugs RPA 102 (Primary)
  • Indications Anthrax
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors VaxGen
  • Most Recent Events

    • 14 Mar 2014 Status changed from planning to discontinued (vaccine development discontinued by VaxGen).
    • 18 Sep 2010 Status changed from suspended to planning, according to an Emergent BioSolutions media release.
    • 15 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top